Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc. (LIXT) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · LIXT · as of Jun 30, 2023
Ownership Breakdown
1
Institutional Holders
▼ 10 vs Q1
$205,240
Total Inst. Value
▼ $1.03M vs Q1
12.38M
Shares Outstanding
freeFloat 93.86%
248,084
13F Shares Held
▼ 299,686 vs Q1
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
LIXT largest shareholders · institutional ownership
Q2 2023 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ETHOS FINANCIAL GROUP, LLC pharmaceutical preparations | 248.1K | 1.49% | 1.49% | $205.24M | Jul 19, 2023 | — held |
STATE STREET CORP pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 14, 2023 | EXIT |
VANGUARD GROUP INC pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 14, 2023 | EXIT |
MORGAN STANLEY pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 14, 2023 | EXIT |
TWO SIGMA INVESTMENTS, LP pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 14, 2023 | EXIT |
WELLS FARGO & COMPANY/MN pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 15, 2023 | EXIT |
TOWER RESEARCH CAPITAL LLC (TRC) pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 14, 2023 | EXIT |
EP WEALTH ADVISORS, LLC pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 14, 2023 | EXIT |
NORTHEAST FINANCIAL CONSULTANTS INC pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 8, 2023 | EXIT |
UBS GROUP AG pharmaceutical preparations | 0 | 0.00% | 0.00% | $0 | Aug 11, 2023 | EXIT |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q2 2023 vs prior quarter
Q2 2023
0
Increased
+0 shares0
New Positions
first time holders0
Decreased
−0 shares10
Sold Out
fully exitedNet shares change (top 50)
+0
+0 / −0
Net new holders
-10
0 new / 10 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
LIXT insider trading · insider activity
Source: SEC Form 4
6
Buy transactions
6
Sell transactions
1.00
Buy/Sell ratio
$1M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Porter Stuart D director | May 29, 2026 | Award | 25,000 | — | — | 25.0K | Form 4 ↗ |
Pursglove Geordan Garrett CEO and Chairman of the Board | Apr 15, 2026 | Award | 350,000 | — | — | 350.0K | Form 4 ↗ |
Pursglove Geordan Garrett CEO and Chairman of the Board | Apr 15, 2026 | D-Return | 350,000 | $2.83 | $990.5K | 0 | Form 4 ↗ |
Stazzone Peter Chief Financial Officer | Apr 15, 2026 | Award | 50,000 | — | — | 50.0K | Form 4 ↗ |
Stazzone Peter Chief Financial Officer | Apr 15, 2026 | D-Return | 50,000 | $4.45 | $222.5K | 0 | Form 4 ↗ |
Felix Lourdes director | Apr 15, 2026 | Award | 25,000 | — | — | 25.0K | Form 4 ↗ |
Sawyer Jason David director | Apr 15, 2026 | Award | 25,000 | — | — | 25.0K | Form 4 ↗ |
Felix Lourdes director | Apr 15, 2026 | D-Return | 25,000 | $4.05 | $101.3K | 0 | Form 4 ↗ |
Sawyer Jason David director | Apr 15, 2026 | D-Return | 25,000 | $3.59 | $89.8K | 0 | Form 4 ↗ |
Holloway Michael Andrew director | Apr 15, 2026 | Award | 25,000 | — | — | 25.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Lixte Biotechnology Holdings, Inc. (LIXT) is primarily owned by institutional investors, who hold approximately 2.0% of total shares outstanding. Company insiders own approximately 6.14%, while retail and public investors account for the remaining 91.86%.
The largest institutional shareholder of Lixte Biotechnology Holdings, Inc. is ETHOS FINANCIAL GROUP, LLC, holding approximately 248,084 shares — equal to 1.49% of outstanding shares — as of June 30, 2023.
A total of 1 institutional investors currently hold LIXT stock, with a combined institutional value of approximately $205,240 as of the most recent 13F filing period.
Frequently asked questions
LIXT ownershipLixte Biotechnology Holdings, Inc. (LIXT) is primarily owned by institutional investors, who hold approximately 2.0% of shares. The largest shareholder is ETHOS FINANCIAL GROUP, LLC with a 1.49% stake. Company insiders hold 6.14%. Data sourced from SEC Form 13F as of June 30, 2023.